



## Solenio Therapeutics to Participate in Upcoming Investor Conferences

May 22, 2024 12:00 PM EDT

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Solenio") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:

**Event:** Jefferies Global Healthcare Conference  
**Day:** Wednesday, June 5, 2024  
**Time:** 11:30 AM Eastern Time

**Event:** Goldman Sachs 45th Annual Global Healthcare Conference  
**Day:** Tuesday, June 11, 2024  
**Time:** 4:00 PM ET

A live audio webcast and replay of the events will be available in the Investors section on the Company's website at [www.solenio.life](http://www.solenio.life).

### About Soleno Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit [www.solenio.life](http://www.solenio.life).

**Corporate Contact:**  
Brian Ritchie  
LifeSci Advisors, LLC  
212-915-2578



Source: Soleno Therapeutics